

NDA 208573/S-026

SUPPLEMENT APPROVAL

AbbVie, Inc.
Attention: Raid Ibrahim
Director, Regulatory Affairs
1 North Waukegan Road
Department PA77, Building AP30-4
North Chicago, IL 60064

Dear Mr. Ibrahim:

Please refer to your supplemental new drug application (sNDA) dated and received October 13, 2021, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Venclexta (venetoclax) tablets.

This "Changes Being Effected" sNDA provides for a minor correction of the death rate from 17% to 16% in the US Prescribing Information Section 14.1 Chronic Lymphocytic Leukemia/Small Lymphocytic under 71-Month Follow-Up sub-section. In addition, this supplement contains an editorial edit to include the commodity number for the Applicant's internal tracking purposes.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.



CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (Prescribing Information, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS


Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-*

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.





¹ http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

NDA 208573/S-026 Page 3

Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Denise Felluca, Regulatory Health Project Manager, at 301-796-4574.

Sincerely,

{See appended electronic signature page}

Nicole J. Gormley, MD Director Division of Hematologic Malignancies II Office of Oncologic Diseases Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - o Prescribing Information
 - Medication Guide

⁵ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf





³ For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.

⁴ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NICOLE J GORMLEY 10/22/2021 01:55:45 PM

